Navigation Links
SemBioSys signs option agreement for safflower-produced food ingredient
Date:1/29/2008

r the production of chymosin in plants at significantly lower costs.

About SemBioSys Genetics Inc. (http://www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and animal health markets.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys announces 2007 third quarter results
2. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
3. SemBioSys updates Apo AI development program
4. AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000
5. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
6. University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two
7. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
8. Kiwa Signs Letter of Intent with Huaxing Animal Medicine
9. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
10. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
11. Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)...  Neogen Corporation (NASDAQ: NEOG ) announced today ... plan in accordance with Securities and Exchange Commission rule ... Neogen Corporation, is a minority owner of this entity ... Herbert does not have control of this entity, ... only for a portion of the shares owned by ...
(Date:3/27/2015)... 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , today ... ended December 31, 2014.  The Company ... per share, for the three months ended December 31, ...
(Date:3/26/2015)... March 26, 2015 The Market Element ... a strategic alliance with Designing Gig LLC to provide ... , “Forging this alliance with Designing Gig ... we can extend a comprehensive, end-to-end, digital solution for ... and execution,” said Chuck Miller, president of The Market ...
(Date:3/26/2015)... March 26, 2015 ReliantHeart, Inc., an ... Transonic, a supplier of precision transit-time flow measurement solutions, ... greatly improve the efficiency of the HeartAssist5® ... patients to experience greater mobility and peace of mind. ... miniature flow board, will draw 1/6th of the power ...
Breaking Biology Technology:Neogen CEO adopts 10b5-1 Trading Plan 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... designed to help consulting engineers and other ... GROVE, Ill., April 8 Siemens Building ... Science Solutions Design Guide written expressly for ... looking to design and specify effective and ...
... Kiadis,Pharma reported preliminary clinical data on ATIR(TM) ... Data was presented by the,company,s principal investigator ... Symposium at the Annual European Bone Marrow ... March 30, 2009. Only the 6,highest ranked ...
... Micromet, Inc. (Nasdaq: MITI ), a ... treatment of cancer, inflammation and autoimmune diseases, today ... Journal of Immunotherapy (1) demonstrating the potent anti-tumor ... antigen (CEA) and to CD3 on T cells. ...
Cached Biology Technology:Siemens Offers Life Science Solutions Design Guide for Consulting Engineers 2Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations 2Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 2Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 3Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 4
(Date:3/17/2015)...  MecklerMedia Corporation (OTCQX: MECK) announced its ... ever held in New York City ... 2015 at the Javits Convention Center. ... Acorn Product Development; Axis NJ; c-Link Systems; CoroWare; ... NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; RocketFarm ...
(Date:3/12/2015)... MOUNTAIN VIEW, Calif. , March 12, 2015 ... EDTLOCATION:Online, with Complimentary Registration here: http://bit.ly/1G7Os0L . ... Program Manager Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... future in order to compete in several different ... the market is currently witnessing an uptrend. ...
(Date:3/10/2015)... --  Tute Genomics , pioneer in affordable, accurate and ... company PrimBio Research Institute to be its ... interpretation. PrimBio, a certified Life Technologies Ampliseq ... to support the work of experts on the front ... of exome sequencing services: 1) Targeted Exome and 2) ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3
... about selective serotonin reuptake inhibitors (SSRIs) suggests that these ... like depression and anxiety, have multiple effects on our ... 2010 issue of GENETICS ( http://www.genetics.org ), ... or pathways affected by SSRIs. Such secondary pathways could ...
... at the Buck Institute for Age Research have successfully ... rodents afflicted with Parkinson,s Disease (PD). The research, ... had previously developed, can be used to manufacture the ... paves the way for the use of iPSC,s in ...
... is now clear that RNA plays a major role in ... while also serving as an important tool in functional genomics. ... Review series is providing RNA experts and researchers not only ... also a framework to generate new insights and applications. ...
Cached Biology News:SSRIs may pack more punch at the cellular level than believed 2Scientists successfully use human induced pluripotent stem cells to treat Parkinson's in rodents 2
... is used for single-color real-time detection using ... JOE fluorophores and features a real-time PCR ... from 96 wells, a gene expression macro ... The system includes the optical module and ...
... , CapSure HS and CapSure Macro LCM ... of populations of pure cells from tissue ... Microdissection., Ensure the Integrity of Microdissected ... CapSure LCM Caps have a patented transfer ...
... new MyiQ real-time PCR detection system offers ... common green fluorescent dyes such as FAM ... directly with the iCycler thermal cycler, offering ... Peltier-effect driven performance. The MyiQ real-time PCR ...
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
Biology Products: